Global Immunology Partnering 2014-2020: Deal trends, players and financials


The Global Immunology Partnering 2014-2020: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the immunology partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
December 2020
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

Global Immunology Partnering 2014 to 2020 provides the full collection of Immunology disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.


  • Trends in Immunology partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Immunology partnering agreement structure
  • Immunology partnering contract documents
  • Top Immunology deals by value
  • Most active Immunology dealmakers


Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.


The report takes readers through the comprehensive Immunology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Immunology deals.


The report presents financial deal terms values for Immunology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.


The initial chapters of this report provide an orientation of Immunology dealmaking trends.


Chapter 1 provides an introduction to the report.


Chapter 2 provides an overview of the trends in Immunology dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.


Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.


Chapter 4 provides a review of the leading Immunology deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Immunology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.


Chapter 5 provides comprehensive access to Immunology deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.


Chapter 6 provides a comprehensive directory of all Immunology partnering deals by specific Immunology target announced since 2014. The chapter is organized by specific Immunology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


In addition, a comprehensive appendix is provided with each report of all Immunology partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The report also includes numerous tables and figures that illustrate the trends and activities in Immunology partnering and dealmaking since 2014.      


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Immunology technologies and products.


Report scope


Global Immunology Partnering 2014 to 2020 is intended to provide the reader with an in-depth understanding and access to Immunology trends and structure of deals entered into by leading companies worldwide.


Global Immunology Partnering 2014 to 2020 includes:


  • Trends in Immunology dealmaking in the biopharma industry since 2014
  • Analysis of Immunology deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Immunology deal contract documents
  • Comprehensive access to over 750 Immunology deal records
  • The leading Immunology deals by value since 2014
  • Most active Immunology dealmakers since 2014


The report includes deals for the following indications: AIDS, Allergy, Anaphylactic shock, Graft versus host disease, Inflammation, Other autoimmune, Scleroderma, Systemic lupus erythematosus, plus other immunology indications.


In Global Immunology Partnering 2014 to 2020, available deals and contracts are listed by:


  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication


Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 


The Global Immunology Partnering 2014-2020 report provides comprehensive access to available deals and contract documents for over 750 immunology deals. Analyzing actual contract agreements allows assessment of the following:


  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Immunology Partnering 2014 to 2020 provides the reader with the following key benefits:


  • In-depth understanding of Immunology deal trends since 2014
  • Access Immunology deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Immunology partner companies
  • Comprehensive access to over 750 links to actual Immunology deals entered into by the world’s biopharma companies
  • Indepth review of Immunology deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Immunology opportunities
  • Uncover companies actively partnering Immunology opportunities

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in Immunology dealmaking


2.1. Introduction

2.2. Immunology partnering over the years         

2.3. Immunology partnering by deal type

2.4. Immunology partnering by industry sector

2.5. Immunology partnering by stage of development

2.6. Immunology partnering by technology type

2.7. Immunology partnering by therapeutic indication


Chapter 3 –Financial deal terms for Immunology partnering


3.1. Introduction

3.2. Disclosed financials terms for Immunology partnering

3.3. Immunology partnering headline values

3.4. Immunology deal upfront payments

3.5. Immunology deal milestone payments

3.6. Immunology royalty rates


Chapter 4 – Leading Immunology deals and dealmakers


4.1. Introduction

4.2. Most active in Immunology partnering

4.3. List of most active dealmakers in Immunology        

4.4. Top Immunology deals by value


Chapter 5 – Immunology contract document directory


5.1. Introduction

5.2. Immunology partnering deals where contract document available


Chapter 6 – Immunology dealmaking by therapeutic target


6.1. Introduction

6.2. Deals by Immunology therapeutic target




Appendix 1 – Directory of Immunology deals by company A-Z since 2014

Appendix 2 – Directory of Immunology deals by deal type since 2014

Appendix 3 – Directory of Immunology deals by stage of development since 2014

Appendix 4 – Directory of Immunology deals by technology type since 2014

Further reading on dealmaking

Deal type definitions


About Wildwood Ventures


Current Partnering

Current Agreements

Recent report titles from CurrentPartnering


Table of figures


Figure 1: Immunology partnering since 2014

Figure 2: Immunology partnering by deal type since 2014

Figure 3: Immunology partnering by industry sector since 2014

Figure 4: Immunology partnering by stage of development since 2014

Figure 5: Immunology partnering by technology type since 2014

Figure 6: Immunology partnering by indication since 2014

Figure 7: Immunology deals with a headline value

Figure 8: Immunology deals with upfront payment values

Figure 9: Immunology deals with milestone payment

Figure 10: Immunology deals with royalty rates

Figure 11: Active Immunology dealmaking activity since 2014

Figure 12: Top Immunology deals by value since 2014

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license


A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.


Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

4D Pharma, 7 Hills Pharma, 23andMe, A*STAR Agency for Science, Technology and Research, A*STAR Genome Institute of Singapore, A*STAR’ Institute of Molecular and Cell Biology, Aarhus University Hospital, Aavis Pharmaceuticals, AB2 Bio, Abarca, AB Biosciences, Abbott Laboratories, Abbvie, Abcam, AbCellera, Abcuro, Abide Therapeutics, Abingworth Management, ABL Bio, Ablynx, Abpro, Abreos Biosciences, AbSci, Abzena, Aceso Life Science, AC Immune, Actelion, ActoGeniX, Acucela, AdAlta, Adamis Pharmaceuticals, Adaptate Biotherapeutics, Adaptive Biotechnologies, Adicet Bio, Aditx Therapeutics, Aduro BioTech, Advanz Pharma, Advaxis, Aerocrine, Aevi Genomic Medicine, Aevitas Therapeutics, Affibody, AffyXell Therapeutics, AGC Biologics, Agenus Bio, AgomAb Therapeutics, AIDS Clinical Trials Group, AIDS Foundation Houston, AIDS Foundation of Chicago, Aimmune Therapeutics, AirWare Labs, Akers Biosciences, Akeso Biopharma, Akoya Biosciences, Akrevia Therapeutics, Akriveia Therapeutics, Alder Biopharmaceuticals, Aldeyra Therapeutics, Alector, Alexion Pharmaceuticals, ALK-Abello, Allakos, Allen Institute for Brain Science, AllerGenis, Allergopharma, Alliance for Biosecurity, Alliance for Lupus Research, Allied-Bristol Life Sciences, Alloksys Life Sciences, Almirall, Alpha Cancer Technologies, Alpine Immune Sciences, AltaVoice, Alvotech, Alzheimer's Association, AM-Pharma, Amal Therapeutics, Amegabiotech, American Diabetes Association, Amgen, AMPEL BioSolutions, Amunix, AnaMar, Anergis, Angiocrine Bioscience, ANI Pharmaceuticals, Annapurna Therapeutics, Anokion, Anpac Bio-Medical Science, Anthera Pharmaceuticals, Antibe Therapeutics, AntibioTx, Apeiron Biologics, Apellis Pharmaceuticals, Apocell, Applied BioMath, Aptahem, Aptar Pharma, Aptevo Therapeutics, Aqilion, Aquila BioMedical, Aralez Pharmaceuticals, Aratana Therapeutics, Arbele, Arbutus, Archer Daniels Midland Company, ArcherDX, Arcutis Biotherapeutics, Arena Pharmaceuticals, arGEN-X, argenx, Argonne National Laboratory, Ario Pharma, Armas Pharmaceuticals, Array Biopharma, Arrien Pharmaceuticals, ARS Pharmaceuticals, Artelo Biosciences, Artisan Bio, Artizan Biosciences, Asahi Kasei, Asana Biosciences, AskAt, Aslan Pharma, Astellas Pharma, Astion Pharma, AstraZeneca, Atara Biotherapeutics, ATGen Global, Atomwise, Atreca, Aurinia Pharmaceuticals, Avacta, Avactis Biosciences, Avalere Health, Avalon GloboCare, Avectas, Avid Bioservices, Avidity Biosciences, Avillion, Avrobio, Axela, AyoxxA Biosystems, Bausch & Lomb, Baxalta, Baxter International, Bayer, Bayer Animal Health, Baylor College of Medicine, BCD Bioscience, Beacon Discovery, Beactica, Beckman Coulter, BeiGene, Beijing Yuan Jian Health Management, Bellicum Pharmaceuticals, Benaroya Research Institute, Berg, Berkeley Lights, Bertin Pharma, Be The Match BioTherapies, Bial, Bicycle Therapeutics, Bill and Melinda Gates Foundation, Bina Technologies, Bio-Cancer Treatment International, Bio-Path, Bio-Techne, BioBright, BioCad Holding, Biocartis, Biocon, bioCSL, Biocytogen, BioDuro, Biogen, Biohaven Pharmaceutical Holding, Bioject Medical Technologies, BiolineRX, Biomedical Advanced Research and Development Authority, BioMed X Innovation Center, Biomunex Pharmaceuticals, BioRap Technologies, BioSense Global, Biosortia Pharmaceuticals, Biotest, Biotest Pharmaceuticals, BirchBioMed, Black AIDS Institute, Bleeding Disorders Foundation, Bloom Burton, Bloom Science, BlueRock Therapeutics, BlueWillow Biologics, Boehringer Ingelheim, Botanisol, Bpifrance, Breathe Active, Brickell Biotech, Bridge Biotherapeutics, Brigham and Women's Hospital, Brii Biosciences, Bristol-Myers Squibb, Broad Institute, Bryn Pharma, Buck Institute for Age Research, Bukwang Pharmaceuticals, BullFrog AI, C4X Discovery, Cabaletta Bio, Cadila Pharmaceuticals, Caelum Biosciences, Calico, California Institute for Regenerative Medicine, Calliditas Therapeutics, Calypso Biotech, Cambridge Enterprise, Camurus, Canadian Council, Canadian Institutes of Health Research, Cancer Genetics, Cancer Research Institute, Cannvalate, Cantargia, Carbiotix, Cardinal Partners, CareFirst BlueCross BlueShield, Carna BioSciences, Casebia Therapeutics, Catalyst Pharmaceuticals, CB2 Therapeutics, Celgene, Cellgen Diagnostics, Cell Mogrify, CellSight Technologies, Center for iPS Cells Research and Application, Centers for Disease Control and Prevention, Centogene, Central Institute for Experimental Animals, Centre Leon Berard, Centre National de la Recherche Scientifique, Centurion, Charite Universitatsmedizin Berlin, Charles River Laboratories, Checkpoint Therapeutics, Cheplapharm Arzneimittel, Children's Hospital Boston, Chong Kun Dang, Chr Hansen, ChromaDex, Chromocell, Chugai Pharmaceutical, Chugai Pharma Marketing, Cigna Healthcare, Cipher Pharmaceuticals, Circassia, Circuit Clinical, Circulogene, City of Hope, Clinigen, CMS Medical, Coherus Biosciences, COI Pharmaceuticals, Columbia University, Commense, Complix, Compugen, ConsortiaTX, Corbin Therapeutics, Corbus Pharmaceuticals, CoreRx Pharma, Cornell University, Corrona, Crescendo Biologics, CRISPR Therapeutics, Cristal Therapeutics, Cromos Pharma, Crown Bioscience, Crystal Bioscience, CSL Behring, CSPC Pharmaceutical Group, Cue Biopharma, Curable, Curadev Pharma, Curetis, CureVac, Cureveda, Cyclacel Pharmaceuticals, Cyclenium Pharma, Cyclofluidic, CyDex, Cygnus, Cynata Therapeutics, Cynvenio, Cystic Fibrosis Foundation Therapeutics, CytoAgents, Cytobank, CytomX Therapeutics, CytoReason, Cytori Therapeutics, Cytovance Biologics, Daewoong Pharmaceutical, Daiichi Sankyo, Dako, Dalhousie University, Dana-Farber Cancer Institute, Dartmouth College, DAS Therapeutics, DBV Technologies, DecImmune Therapeutics, Denali Therapeutics, DendroCyte, Department of Defense, Devonian Health Group, DiaCarta, Dianomi Therapeutics, Diatheva, DKSH, DNAtrix, DNX Biopharmaceuticals, Dong-A ST, Dragonfly Therapeutics, Dualogics, Duke-NUS Graduate Medical School Singapore, Duke University, Eastar Industries, Eddingpharm, Egle Therapeutics, Eisai, Eisai Inc, Eli Lilly, Elpis Biomed, ElsaLys Biotech, Elton John AIDS Foundation, EMD Serono, Emerge Health, Emory University, Enable Biosciences, Enamine, EnBiotix, Encycle Therpaeutics, Endo Pharmaceuticals, Enesi Pharma, Ensemble Therapeutics, Enterome Bioscience, Entos Pharmaceuticals, Enumeral Biomedical, EpimAb Biotherapeutics, Epirus Biopharmaceuticals, Epivax, Equillium, Erasmus University Medical Center, Escient Pharmaceuticals, Essex Bio-Technology, eTheRNA immunotherapies, Eton Pharmaceuticals, Eurofins Discovery, Eurofins Scientific, European Bioinformatics Institute, European Union, Eutilex, Evelo Biosciences, Everest Medicines, Evotec, Ewopharma, Exagen Diagnostics, ExeGi Pharma, Expedeon, ExScientia, F-Star, Federal Ministry of Health (Germany), Feinstein Institute for Medical Research, Feldan Therapeutics, Ferring Pharmaceuticals, Fibrocell Science, Five Prime Therapeutics, Fluidigm, Folia Biotech, Food Allergy Research & Education, Food and Drug Administration (FDA), Fortress Biotech, Foundation Medicine, Fred Hutchinson Cancer Research Center, French Alternative Energies and Atomic Energy Commission, French National Genotyping Center, French National Institute for Agricultural Research, Fresenius Kabi Pharmaceuticals, FSD Pharma, Fuji Pharma, Fundacion Progreso y Salud, G2B Pharma, Galapagos, GammaDelta Therapeutics, Gateway Hemophilia Association, GC LabCell, GE Healthcare, GEMoaB, Gencia Biotech, Genentech, GeneQuantum Healthcare, Genethon, Genfit, Genmab, Genomic Testing Cooperative, GenScript Biotech, GentiBio, Georgetown University, George Washington University, GeoVax, Gesynta Pharma, Gilead Sciences, GlaxoSmithKline, Glenmark Pharmaceuticals, Global Centers for Therapeutic Innovation, Global Stem Cell Technology, GlycoT Therapeutics, Gossamer Bio, Gradalis, Great Ormond Street Hospital (GOSH), Gritstone Oncology, Grunenthal, GT Biopharma, Guardant Health, Hadasit Medical Research Services and Development, Halfpenny Technologies, HalioDx, Halozyme Therapeutics, Hamilton Company, HanAll Pharmaceuticals, Hanmi Pharmaceutical, Harbour Biomed, Harvard University, Heat Biologics, HemispheRx Biopharma, Hemophilia Foundation of Southern California, Henlius Biotech, HiFiBio, Highline Therapeutics, Hikma Pharmaceuticals, Hob Diagnostics, Hoffmann La Roche, Hookipa Pharma, Horizon Pharma plc, Hospices Civils de Lyon, Hospira, Hospital for Special Surgery, Hoth Therapeutics, Hualan Genetic, Humanigen, I-mab, iBio, Icahn School of Medicine at Mount Sinai, IcanoMAB, ICM, Idera Pharmaceuticals, IDIS Pharma, Idorsia, IFM Therapeutics, Igenica, ILTOO Pharma, ImaginAb, ImCheck Therapeutics, IMIDomics, Immatics Biotechnologies, Immatics US, Immugenyx, ImmunArray, Immune Deficiency Foundation, Immune Design, Immuneed, Immune Pharmaceuticals, ImmuNext, Immunic, ImmunoChina Pharmaceuticals, Immunogenesis, Immunomedics, Immunomic, Immunovia, Immunscape, ImmuPharma, IncellDx, Incyte, Indapta Therapeutics, Indee Labs, InDex Pharmaceuticals, Indigo Biosciences, Infinity Pharmaceuticals, InflamaCORE, InMed Pharmaceuticals, Innate Pharma, Innovate UK, Innovative Genomics Initiative (IGI), Innovative Targeting Solutions, Innovent Biologics, Innovus Pharmaceuticals, Inotrem, Inovalon, Inovio Pharmaceuticals, Inserm Transfert, Inspirotec, Institut Curie, Institute for Basic Science, Institute for Bioscience and Biotechnology Research, Institute for Research in Immunology and Cancer – Commercialization of Research, Institute for the Promotion of Innovation by Science and Technology in Flanders, Institute of Child Health, Institut Pasteur, Institut Pasteur of Shanghai at the Chinese Academy of Sciences, Intarcia Therapeutics, Integrated BioTherapeutics, Intellia Therapeutics, Intellikine, International AIDS Vaccine Initiative, Intrexon, Intrommune Therapeutics, Invitae, Ionis Pharmaceuticals, IONTAS, IP Biotech, Ipca Laboratories, iReceptor Plus, ISA Scientific, ISIS Innovation, IsoPlexis, iTeos Therapeutics, Itus, J-Network, Jacobio Pharmaceuticals, JAGUAHR Therapeutics, Janssen Biotech, Janssen Diagnostics, Janssen Research & Development, Janssen Therapeutics, Janus Pharmaceuticals, Japan Tobacco, Jazz Pharmaceuticals, JDP Therapeutics, Jeffrey Modell Foundation, Jiangsu Chia Tai Tianqing Pharmaceutical, Jiangsu Hansoh Pharmaceutical, Jiangsu Hengrui Medicine, Jiangsu QYuns Therapeutics, Jnana Therapeutics, Johns Hopkins Kimmel Cancer Center, Johns Hopkins Medicine (JHM), Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, Jubilant Pharma, Juno Therapeutics, Kaken Pharmaceutical, Kalbe Genexine Biologics, Kaleido Biosciences, Kamada, Karolinska Institute, Karyopharm Therapeutics, KBI BioPharma, KBP BioSciences, Kedrion Biopharma, Keio Gijuku University, Kennedy Trust For Rheumatology Research, Kiadis Pharma, Kimberly-Clark, Kineta, King's College Hospital, Kiniksa Pharmaceuticals, Kissei Pharmaceutical, Kite Pharma, Klaria, Knight Therapeutics, Kobe University, KYE Pharmaceuticals, Kymab, Kymera Therapeutics, Kyverna Therapeutics, Lannett, Laurel Venture Capital, Lead Discovery Center, Lead Pharma, Leads Biolabs, Lee's Pharmaceutical, LegoChem Biosciences, Leiden University, Leidos, LEO Pharma, Les Laboratoires Servier, Leukemia & Lymphoma Society, LG Life Sciences, LifeArc, LifeMax Laboratories, Ligand Pharmaceuticals, Lipum, LNC, Lonza, Lorna Linda University, LTL Pharma, Lubeck Institute of Experimental Dermatology, Luminex, Lumiphore, Lupin, Lupus Foundation of America (LFA), Lupus Research Alliance, Lupus Research Institute, Lupus Therapeutics, Lurie Children's Hospital of Chicago, Luye Pharma Group, Lynk Pharmaceuticals, MaaT Pharma, MAB Discovery, Mablife, mAbXience, Macrogenics, Macrophage Pharma, Magenta Therapeutics, Magnetic Insight, Mallinckrodt Pharmaceuticals, Mariel Therapeutics, Marinomed Biotechnologie, Massachusetts General Hospital, Massachusetts Institute of Technology, Massachusetts Life Sciences Center, Max-Planck, Maxcyte, Mayo Clinic, McGill University, MD Anderson Cancer Center, MD Biosciences, Medac, Medical Research Council, Medical University of South Carolina, Medical University of Vienna, Medical University South Carolina, Medidata Solutions, MediGene, MedImmune, Memorial Sloan Kettering Cancer Center, Merck and Co, Merck KGaA, Merck Sharpe & Dohme, Merus, Mesoblast, Metrion Biosciences, MGC Pharma, Microbio Shanghai, Microdrop, Micro Labs, Microsoft, Midatech, MIGAL Galilee Research Institute, MilliporeSigma, MIODx, MISTR, Mitra Biotech, Mitsubishi Tanabe Pharma, Moderna Therapeutics, ModiQuest Research, Momenta Pharmaceuticals, Monash University, Morphic Therapeutic, MorphoSys, Mor Research Applications, Mount Sinai Health System, Mount Sinai Medical Center, Mount Tam Biotechnologies, Mundipharma, Munich Technical University, Mustang Bio, My Brother’s Keeper, Mylan Pharmaceuticals, Mytide Therapeutics, NanoPass Technologies, NantWorks, Napo Pharmaceuticals, National Cancer Institute, National Heart, Lung and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute of Dental and Craniofacial Research (NIDCR), National Institute of General Medical Sciences, National Institutes of Health, National Organization for Rare Disorders, National Science Foundation, National University of Singapore, Nature Technology, Nektar Therapeutics, Neostell, Neovacs, Neovii Pharmaceuticals, NeoX Biotech, Neptune Technologies & Bioressources, Nestle Health Science, NeuClone, Neumedicines, NeuroCycle Therapeutics, NeuroVive Pharmaceutical, Newsoara Biopharma, New York Medical College, New York University, New York University School of Medicine, Neximmune, NextCure, Nexvet, Nichi-Iko Pharmaceutical Co, Nimbus Therapeutics, Ningbo Tai Kang Medical Technology, NJCTTQ, Nodality, Noga Therapeutics, North Carolina State University, Northwestern University, Novalere, Novant Health, Novartis, NovaSAID, Noveome Biotherapeutics, NovImmune, Novo Nordisk, Novozymes, Nuevolution, Numab, Nurix, Nuvo Pharmaceuticals, NYU Langone Medical Center, Oblique Therapeutics, Ocata Therapeutics, Oklahoma Medical Research Foundation, Omeros, Oncobiologics, Oncologie, OncoQuest, OncoSec Medical, Onegevity, Oneness Biotech, oNKo-innate, Ono Pharmaceutical, OraSure Technologies, Orca Pharmaceuticals, Orchard Therapeutics, Orebro University, Orexo, Ortho-Clinical Diagnostics, Osaka University, OSE Immunotherapeutics, OSEO, Oslo University Hospital, Ospedale San Raffaele, Owlstone Medical, Oxford University Hospitals NHS Trust, Padlock Therapeutics, Pandion Therapeutics, Panorama Research, Panther Biotechnology, Paragon Bioservices, Parvus Therapeutics, Pathios Therapeutics, PatientsLikeMe, Peking University, Pelican Therapeutics, Pendopharm, PeptiDream, Perelman School of Medicine, Pfizer, Phanes Therapeutics, PharmEste, Pharming Group, Pharmstandard, Pharnext, Philogen, Phio Pharmaceuticals, PhoreMost, Pieris, Pierre Fabre, Pinnacle Clinical Research Center, Pionyr Immunotherapeutics, Plasticell, Plexision, Pluristem Therapeutics, Pneuma Respiratory, Potenza Therapeutics, PPD, Precision BioSciences, Precision for Medicine, PredictImmune, Prestizia, PreventionGenetics, Principia Biopharma, ProBioGen, ProciseDx, Progentec Diagnostics, Project Inform, Promethera Biosciences, Prometheus Laboratories, Protagen, Prota Therapeutics, Proteona, ProThera, ProtoKinetix, Provention Bio, ProvideGx, Provider Network of America, Proximagen Group, Pulmatrix, Purdue Pharma, PureTech Health, Pyramid Biosciences, Q32 Bio, Qiagen, Quartet Medicine, Queensland Institute of Medical Research (QIMR), Quest PharmaTech, R-Pharm, R-Tech Ueno, Rabin Medical Center (Beilinson Hospital), Ragon Institute, Ra Pharmaceuticals, Recipharm, Recordati, RedHill Biopharma, Regeneron Genetics Center, Regeneron Pharmaceuticals, Repertoire Genesis, Repurpose.AI, Research Foundation to Cure AIDS, RespiVert, ReveraGen BioPharma, Revive Therapeutics, Rheonix, Rheos Medicines, Richard King Mellon Foundation, RIKEN Research Institute, RMX Biopharma, Roche, Rogne Bioscience, Roivant Sciences, Rosetta Genomics, Roxall, Ryvu Therapeutics, S-TARget, SAB Biotherapeutics, Salix Pharmaceuticals, Samsung Bioepis, Sangamo BioSciences, Sanofi, Sanofi-Aventis, Santhera Pharmaceuticals, Saol Therapeutics, Sartorius Stedim Biotech, SATT Lutech, Scholar Rock, Schreiner Group, Schrodinger, SciCann Therapeutics, Science Exchange, Scienion, Sciex, Scleroderma Research Foundation, Scripps Research Institute, Sean N Parker Center for Allergy Research, Seattle Children's Hospital, Seattle Childrens Research Institute, Seattle Genetics, Second Genome, Sekris Biomedical, Selecta Biosciences, Selecxine, Selexis, Sementis, Seneca Biopharma, Sengenics, SenzaGen, Seqirus, Serametrix, SeraNovo, Seres Therapeutics, Serum Institute of India, Sevion Therapeutics, Shandong Fontacea Pharmaceutical, Shanghai Model Organisms Center, Shattuck Labs, Shin Nippon Biomedical Laboratories, Shire Laboratories, Shire Pharmaceuticals, Sigma-Tau, Sigmoid, Silence Therapeutics, Simbec Research, Simcere Pharmaceuticals, Singota Solutions, Sirona Biochem, Sitryx, Skyhawk Therapeutics, SomaLogic, Sonora Quest Laboratories, Sorrento Therapeutics, Sosei, Sosei Heptares, Splicos, Spring Bank Pharmaceuticals, SQI Diagnostics, St. Jude Children's Research Hospital, STADA Arzneimittel, Stallargenes, Stanford University, Stanford University School of Medicine, Stellar Biotechnologies, Stony Brook University, Stryker, Sutro Biopharma, Swedish Orphan Biovitrum, Swiss Commission for Technology and Innovation, Swixx Biopharma, Sygnature Discovery, Symbiotix Biotherapies, Symphogen, Synthorx, Takeda Pharmaceutical, Takeda Ventures, Tango Therapeutics, Targeted Medical Pharma, Tavotek Biotherapeutics, Teijin, Tel Aviv Sourasky Medical Center, Telix Pharmaceuticals, TeneoBio, Tennessee Hemophilia, Tessa Therapeutics, Tetra Bio-Pharma, Tetragenetics, Teva Pharmaceutical Industries, TG Therapeutics, The Elizabeth Taylor AIDS Foundation, The Hospital for Sick Children, The Innovation Fund, The International AIDS Vaccine Initiative, The Myositis Association, The Parker Institute For Cancer Immunotherapy, Theradiag, Theravance Biopharma, Thermo Fisher Scientific, Thomas Jefferson University, Thorne Research, Tiziana Life Sciences, Tizona Therapeutics, T Med, Tmunity Therapeutics, Topas Therapeutics, Tow Foundation, Traaser, TransBio, Transgene, Transimmune, TransThera, TrialSpark, Triumvira Immunologics, True Diagnostics, True North Therapeutics, Tsinghua University, Turgut Ilaclari, Twist Bioscience, TxCell, Ubiquigent, UCB, Ultimovacs, Unilife, University College London, University Health Network, University of Alberta, University of Arizona, University of British Columbia, University of Calgary, University of California, San Diego, University of California Berkeley, University of California Los Angeles, University of California San Francisco, University of Cambridge, University of Chicago, University of Cincinnati, University of Colorado, University of Connecticut, University of Debrecen, University of Dundee, University of Edinburgh, University of Florida, University of Geneva, University of Houston, University of Kiel, University of KwaZulu-Natal, University of Lethbridge, University of Manchester, University of Maryland School of Medicine, University of Massachusetts, University of Massachusetts, Amherst, University of Massachusetts Medical School, University of Michigan, University of Minnesota, University of Mississippi, University of Montreal, University of Natural Resources and Life Sciences, University of North Texas Health Science Center, University of Oxford, University of Pennsylvania, University of Queensland, University of Sheffield, University of Sherbrooke, University of South Carolina, University of Texas Southwestern Medical Center, University of Toronto, University of Utah, University of Verona, University of Virginia, University of Washington, University of Wisconsin-Madison, University of Zurich, Uppsalagruppen Medical, Upsher-Smith, Valneva, Vanderbilt University, Variant Pharmaceuticals, Vedanta Biosciences, Velocity Pharmaceutical Development, Verily, ViaMune, Viela Bio, Vifor-Fresenius Medical Care Renal Pharma Ltd, Vinnova, Vitaeris, Vitesse Biologics, Vium, Vividion Therapeutics, Vivoryon Therapeutics, Voluntis, vTv Therapeutics, Vycellix, Washington State University, Watson Laboratories, Weill Cornell Medical College, Wellcome Trust Sanger Institute, WellGen, Willow Biosciences, Windgap Medical, Wisconsin Alumni Research Foundation, Worldwide Clinical Trials, Wuhan Kindstar Diagnostics, WuXi Biologics, WuXi NextCODE Genomics, X-chem, X4 Pharmaceuticals, Xencor, Xilio Therapeutics, XL-Protein, Xoma, XTL Biopharmaceuticals, Y-Biologics, Yale University, Yeda Research and Development Company, Yisheng Biopharma, Yissum Research Development, ZAI Laboratory, Zealand Pharma, Zebra Biologics, Zenoaq, Zenyaku Kogyo, Ziopharm Oncology, Zylo Therapeutics, Zymeworks, ZyVersa Therapeutics

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.